Ipamorelin Peptide Profile
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively binds to the ghrelin/growth hormone secretagogue receptor (GHS‑R1a), mimicking the natural hunger hormone ghrelin to stimulate endogenous growth hormone (GH) release from the pituitary gland without significantly increasing cortisol or prolactin levels. It was originally developed as a research tool and investigated in early clinical trials, including for postoperative ileus, but lacks FDA approval for medical use and is generally classified as an investigational peptide. Ipamorelin’s selective mechanism results in a targeted GH‑releasing effect, distinguishing it from older GH secretagogues by producing GH increases with minimal impact on other hormone axes. It has been explored in research for its potential to support lean muscle mass, fat metabolism, recovery, sleep enhancement, and anti‑aging effects, though robust human clinical evidence remains limited and its use outside research settings is not recommended. Ipamorelin is sometimes paired with analogues such as CJC‑1295 in investigational peptide protocols to achieve synergistic GH release.
Mechanism & Effects (Research Context)
• Selective GH secretagogue that increases plasma GH levels while minimally affecting ACTH, cortisol, prolactin, or other endocrine hormones.
• Potential support for lean muscle, lipolysis, recovery, and sleep quality through GH‑mediated pathways.
• Researched for effects on bone growth and weight gain in preclinical models.
Dosing Chart (Experimental / Community Protocols)
| Parameter | Suggested Range | Frequency | Route | Notes |
| Typical peptide dose | 300–500 mcg | 1–2 ×/day | Subcutaneous | Common community dosing; not clinical guidance
| Body‑weight based | ~0.045–0.05 mg/kg | Daily | Subcutaneous | Evening timing to mimic natural GH rhythm
| Stacking (with CJC‑1295) | 100–300 mcg | 1–2 ×/day | Subcutaneous | Used to amplify GH release in investigational protocols
Safety & Regulatory Notes
• Ipamorelin is not approved by the FDA for clinical use and is often labeled “research use only.”
• Use in sports is prohibited by anti‑doping agencies due to GH‑stimulating properties.
• Reported effects are primarily based on research or anecdotal protocols; long‑term safety data are limited.
References (APA):
Ipamorelin. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Ipamorelin
Ipamorelin dosage guide: optimal protocols for recovery and muscle growth. (2025, July 3). Swolverine.com.
Ipamorelin peptide | Growth hormone support. (2025). Paragon Sports Medicine.
Dosing guidelines for ipamorelin for growth hormone stimulation. (2025, Oct 10). DrOracle.ai.
Clinical usage of ipamorelin. (2025, Jul 30). DrOracle.ai.
